{"name":"Ligand Pharmaceuticals","slug":"ligand","ticker":"LGND","exchange":"NASDAQ","domain":"ligand.com","description":"Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.","hq":"San Diego, CA, USA","founded":0,"employees":"47","ceo":"Todd Davis","sector":"Royalty Aggregator / Platform Technology","stockPrice":206,"stockChange":0.9,"stockChangePercent":0.44,"marketCap":"$4.1B","metrics":{"revenue":141102000,"revenueGrowth":39.4,"grossMargin":64.3,"rdSpend":81182000,"netIncome":124453000,"cash":733521024,"dividendYield":0,"peRatio":33.6,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Captisol-enabled Axitinib patent cliff ($1.4B at risk)","drug":"Captisol-enabled Axitinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Ligand Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Ligand Pharmaceuticals reported its fourth quarter and full year 2023 financial results, with revenue of $143.4 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Ligand Pharmaceuticals Enters into Agreement with Pfizer to Develop and Commercialize Novel Therapies","summary":"Ligand Pharmaceuticals entered into an agreement with Pfizer to develop and commercialize novel therapies for the treatment of certain cancers.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"regulatory","headline":"Ligand Pharmaceuticals Receives FDA Approval for Captisol-enabled Formulation of Pfizer's Axitinib","summary":"Ligand Pharmaceuticals received FDA approval for a Captisol-enabled formulation of Pfizer's axitinib, a tyrosine kinase inhibitor.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPeC0yOEhKWW1BbnZEcUVPbjZUQnQxaEs5cFRQWWJieXZUM25MMDJPcjBrVTAyZDRXZDI2clU0OHUxeEtsUnBnX1JHcG52dDdvYXZnQnBsaUhNeG0xcVNEWURzbmlrRWo0dElmTHFHN29mVE5MUGR5QUhpTzdVRDdkc2V4c2JmVXZtUlpjakxnMUlXakpwaWtwNjdEcnR5TXcxOUhYbnBuejhaaVN4MFVJSEhGTC1aYjNuamdvaDY2RXUxTk5NX0F2eUxacWVsV1pLek8wbVYxNlFNc3Ri?oc=5","date":"2026-03-27","type":"pipeline","source":"The Motley Fool","summary":"Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know - The Motley Fool","headline":"Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPQ2pDMVVlVVpScDVDSTcyS0pEUHRRNFhJYXI4alhwM3NSZlBpTHJfVjVpVElIUk5nZ2ZFbXpVNW80c3Jwb0VrNkRnd3VTUWFnWHktVGhyTUpoemVWT1ozUzROSWMyMDFqTFM4LWdvZjR4a1JfOXNGMlZVVDBHeUt4c0t1d3UxcEYtQTVvNmNIZ2NaaE1SR2RIUHl3MEZLVm1tRENRTlB5Tnpxc0ZoNEgzMDh1VFdEdEFuWUZGODFTcFlSOWhUVTRZ?oc=5","date":"2026-03-18","type":"pipeline","source":"Seeking Alpha","summary":"Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model - Seeking Alpha","headline":"Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE0yeFNhbUd6YXJySWxHNDZqNHl4S3lwT2Q5Q0o1V0dVSDlVaDZMN2dSM3MxQWthbzA0VGZWVUJPNGUxN3FlbTZBaEtrQkJvMk1WYlRPbWxReHdYSmlwbnc?oc=5","date":"2026-03-16","type":"earnings","source":"Stock Titan","summary":"Latest LGND News - Ligand’s Third Quarter Financial Results to... - Stock Titan","headline":"Latest LGND News - Ligand’s Third Quarter Financial Results to...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNZXNPLWFPbnBVUXJoaGVtLV9xRmRsYm15cjUydnA5WmgzMURZQTRmVVFMYzJYWVVfdnplMTRCWFhxaXZ5NTJRUFVJbUNRaEplTmxfSXhwTEVGNkxzbTUzWi1ITTBrLVE2Yy05akM4a2R3SUlEYWtJaG9naDdwc1lXNlBfSmlmOWFzbWxnaXIzbWpRb1JLOVJSVnNJMDhDX3ZKRnFTbnZqVGl1RnNGSVp5c0hTanV6MGRBNkpTX095YTdPTWh4Ykg5My1WUGtNaW90OTBfSXFQVVB5QQ?oc=5","date":"2026-03-06","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% - Investor's Business Daily","headline":"This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPVUpyeFZFMlY3VFlTRjZpOHg2QnVKWURnc3VOdnhMai1QSF9Da2ZoTFE2X2FTbkV4Ul8wVjlIc3hodkstbW5PTGtJZWNGRHZMUHN3ZjRfblcyaUM4TkVqNHg4MWJPMWdqa2NMV2Npa1hORkdXQ1lVR1FWV2dOT2FmWmZkSjFLd3A2XzJrSjR1b0JOeVN4SW1peUlR?oc=5","date":"2026-02-26","type":"earnings","source":"Quiver Quantitative","summary":"LIGAND PHARMACEUTICAL ($LGND) Releases Q4 2025 Earnings - Quiver Quantitative","headline":"LIGAND PHARMACEUTICAL ($LGND) Releases Q4 2025 Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQYktqckxFOUNDUkpGbHM4cmdsdG5CeXBkY29hWm4yb0R2cktYSGdKNXVDSC1qUG9FUUd4VTl4SnJsTVN2VjNRVjJFWG9fZnVFbmFPTzljRlhmemFRUkpYUHMtenlYZW5kbE55eU9qZWJqbGZpTjY0Y1FFY1BFWW0yM3dBQXZQakNMS2xtNXlHcUVYZEFRazZzTnNWVDhXNXUzdXZldUJEYmI2QnhXNDV4bXBZUjJ0TGxwbnk4Z2FQb294S0pIUHljbg?oc=5","date":"2026-01-30","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth - Investor's Business Daily","headline":"This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxQcUVPQk5vNUpkb3Z5Y2hMcnhiZWVPQzg0VFk1V3diSi1sNHZrazd6OGttNUxBN25wVXRjdTZqaVJEaGZ5REpkMU5MYWxCN0xCaHQ1WFhTZ0U2U01MeGc5QnZ4RC1wS1FFZGZZMFdNck1feDA4SmlWSHhkekszeU9mM2IyRU9tcmxFanV1cnZXT1gtV1M3TmxORVI4Wks5b2dXZ3NNX0ZwT0RDbVM3UUlBRHByQkhvb25DbTVjS0ZJVUV0MXQ5VlFwNEV0Z2h0bjNVZ0Y4VEExMG1acjZvTkZYcmttSWl6TXRxM1lOTdIB8gFBVV95cUxPSlczQXJ5ZlFMX05OSnlYdl94UHkzQU9PTHNfWEV6NU5ZbUNFOHJZaWwzeWRDVFJRYTZ1aTc3VFQ2UnpHWXBRenZVemxTdWRDMV9QTnVwRnVST29yc2RYUHhQMFNWVGVsUEoydUc2c3QycGE1aTM0a25RV25PRUtRUm9uODltc0dYa3FuREpKT1RNeVVfLVRtaEZWNzBlVmh2c3lqYUptN29XeTFXOWRXUzdKcEFUZTJQUG12QjlsZjA5eWFmS3pzVld4RmFkdWwySXFYbWp5dDV4TXdHaTNDWUdOdTl0U2tZZF8yOEE5dkdCZw?oc=5","date":"2026-01-07","type":"pipeline","source":"simplywall.st","summary":"Ligand Pharmaceuticals Insiders Sell US$2.8m Of Stock, Possibly Signalling Caution - simplywall.st","headline":"Ligand Pharmaceuticals Insiders Sell US$2.8m Of Stock, Possibly Signalling Caution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNdGlUd0Z1LU9ZTUc3TkI4UjNNVlhsNlh1TGowQlV4em5COVBlaGFXUzZnRGxyTS0xRTJEM3VNNWVpdXlsNEJONUpnZ1VaOFpTQVd3T1ZkbkdZdE5kczNiVTNVU01McE9rZWxwREkwMm4waGlvaDBaRXUtRjVWSU4yN3J4QW1ReDFkMzdrZlROa19NWGJaaHlXZWlsYUdEdTR6T3Qybmk4Y0NzQ2xFcm9Sbk1CWVY2UQ?oc=5","date":"2025-12-18","type":"pipeline","source":"Stock Titan","summary":"Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels - Stock Titan","headline":"Ligand Pharmaceuticals (NASDAQ: LGND) outlines Athira investment update and disclosure channels","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPZEtJQjF4Sm1qMzlCalVxN3lOVFFTQW9BYTBOYUhnMnNjVHFYYUE3aXBNVGp4dWtnYWVueHhkZXlIcHRqN1NMZDZheExlUUNwdmtMLTBDWGI3dXR4NlRzQmx1ODdGUlFlUHZNem9iRHBOSmxfRXljYXNud0x2N2FNZWsyRHlvaVRoajFYY0hma1VBd3hu?oc=5","date":"2025-11-20","type":"pipeline","source":"Investor's Business Daily","summary":"Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year - Investor's Business Daily","headline":"Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE4wQktXMEFHTWFSck1xNmY0cGlfNGZoRXZyWG1hQ1NTSEtGUmNMVjY2UHIxWFJ1ZGVvR3M3QkdybldhclZkcUEwS1EzZU9zZw?oc=5","date":"2025-10-30","type":"pipeline","source":"Stock Titan","summary":"Latest LGND News - Ligand Advances Strategic Growth with Expan... - Stock Titan","headline":"Latest LGND News - Ligand Advances Strategic Growth with Expan...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-10","type":"pipeline","source":"simplywall.st","summary":"Ligand Pharmaceuticals (NASDAQ:LGND) delivers shareholders solid 26% CAGR over 3 years, surging 7.7% in the last week alone - simplywall.st","headline":"Ligand Pharmaceuticals (NASDAQ:LGND) delivers shareholders solid 26% CAGR over 3 years, surging 7.7% in the last week al","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE53eUI5akxObjhHcHJCTmg1MlZxUjFUVGlXdF92M2dHSHpSZUtPZzZPNU1YUXYyUDFVNFpvMndITnFZSklQd2NqT0VwRlliMURo?oc=5","date":"2023-12-22","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"Captisol-enabled Axitinib","drugSlug":"axitinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Biogen","Janssen Pharmaceuticals"],"therapeuticFocus":["Oncology","Pain"],"financials":{"source":"sec_edgar","revenue":141102000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":141102000,"period":"2017-12-31"},{"value":50465000,"period":"2017-12-31"},{"value":33375000,"period":"2017-09-30"},{"value":27995000,"period":"2017-06-30"},{"value":29267000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":81182000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":124453000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1560637000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":206,"previousClose":205.1,"fiftyTwoWeekHigh":227.92,"fiftyTwoWeekLow":93.58,"fiftyTwoWeekRange":"93.58 - 227.92","fiftyDayAverage":198.11,"twoHundredDayAverage":177.02,"beta":1,"enterpriseValue":3807948032,"forwardPE":20.8,"priceToBook":4,"priceToSales":15.32,"enterpriseToRevenue":14.2,"enterpriseToEbitda":47.03,"pegRatio":0,"ebitda":80974000,"ebitdaMargin":30.2,"freeCashflow":87089504,"operatingCashflow":49359000,"totalDebt":451540992,"debtToEquity":44.4,"currentRatio":22.23,"returnOnAssets":2.4,"returnOnEquity":13.5,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":10,"targetMeanPrice":245.1,"targetHighPrice":277,"targetLowPrice":220,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":1278028800,"insiderHeldPercent":2.5,"institutionHeldPercent":105.6,"sharesOutstanding":19941141,"floatShares":19465545,"sharesShort":1458857,"shortRatio":7.24,"shortPercentOfFloat":7.3,"epsTrailing":6.13,"epsForward":9.9,"revenuePerShare":13.86,"bookValue":51.44,"officers":[{"age":64,"name":"Mr. Todd C. Davis Ph.D.","title":"CEO & Director"},{"age":54,"name":"Mr. Octavio  Espinoza","title":"Chief Financial Officer"},{"age":50,"name":"Mr. Andrew T. Reardon J.D.","title":"Chief Legal Officer & Secretary"},{"age":null,"name":"Mr. Paul J. Hadden","title":"Senior Vice President of Investments & Business Development"},{"age":46,"name":"Ms. Melanie J. Herman CPA","title":"Executive Director of Investor Relations and FP&A"},{"age":null,"name":"Dr. Keith  Marschke Ph.D.","title":"Senior Vice President of Biology & Scientific Affairs"},{"age":56,"name":"Dr. Vincent D. Antle Ph.D.","title":"Senior Vice President of Technical Operations & QA - Capitsol"},{"age":null,"name":"Mr. Patrick  Lucy","title":"Senior VP & CBO Protein Expression Business"}],"industry":"Biotechnology","irWebsite":"http://investor.ligand.com/Investors/Investor-Overview/default.aspx","website":"https://www.ligand.com","phone":"858 550 7500"}}